54 related articles for article (PubMed ID: 33242992)
1. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.
Acharya B; Saha D; Garcia Garcia N; Armstrong D; Jabali B; Hanafi M; Frett B; Ryan KR
Bioorg Med Chem; 2024 May; 106():117749. PubMed ID: 38744018
[TBL] [Abstract][Full Text] [Related]
2. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors.
Ferreira R; Nilsson JR; Solano C; Andréasson J; Grøtli M
Sci Rep; 2015 May; 5():9769. PubMed ID: 25944708
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors.
Belli C; Curigliano G
Ann Oncol; 2024 May; 35(5):478-480. PubMed ID: 38369014
[No Abstract] [Full Text] [Related]
5. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
[TBL] [Abstract][Full Text] [Related]
6. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
7. The Next Target for NSCLC: Let It Be "RET".
Ahn BC; Zhu VW; Lim SM
J Thorac Oncol; 2020 Dec; 15(12):1803-1805. PubMed ID: 33246592
[No Abstract] [Full Text] [Related]
8. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia-IIb with RET gene mutation p.M918T： A case report.
Jin P; Hu W; Yang Y; Long X; Mo Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 45(10):1261-1265. PubMed ID: 33268590
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Novel Thieno[3,2-
La Monica G; Pizzolanti G; Baiamonte C; Bono A; Alamia F; Mingoia F; Lauria A; Martorana A
ACS Omega; 2023 Sep; 8(38):34640-34649. PubMed ID: 37779971
[TBL] [Abstract][Full Text] [Related]
12. Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
Drewry DH; Potjewyd FM; Bayati A; Smith JL; Dickmander RJ; Howell S; Taft-Benz S; Min SM; Hossain MA; Heise M; McPherson PS; Moorman NJ; Axtman AD
J Med Chem; 2022 Oct; 65(19):12860-12882. PubMed ID: 36111834
[TBL] [Abstract][Full Text] [Related]
13. Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics.
Parate S; Kumar V; Chan Hong J; Lee KW
RSC Adv; 2021 Dec; 12(2):1194-1207. PubMed ID: 35425116
[TBL] [Abstract][Full Text] [Related]
14. Designing Novel Compounds for the Treatment and Management of RET-Positive Non-Small Cell Lung Cancer-Fragment Based Drug Design Strategy.
Ramesh P; Veerappapillai S
Molecules; 2022 Feb; 27(5):. PubMed ID: 35268691
[TBL] [Abstract][Full Text] [Related]
15. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
[TBL] [Abstract][Full Text] [Related]
16. Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Jia CC; Chen W; Feng ZL; Liu ZP
Future Med Chem; 2021 Jan; 13(1):45-62. PubMed ID: 33242992
[No Abstract] [Full Text] [Related]
17. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
18. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
